Blood Res 2015; 50(1):
Published online March 31, 2015
https://doi.org/10.5045/br.2015.50.1.51
© The Korean Society of Hematology
Department of Internal Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, Korea.
Correspondence to : Correspondence to Hye Jin Kang, M.D. Division of Hematology/Oncology, Department of Internal Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, 75 Nowon-gil, Nowon-gu, Seoul 139-706, Korea. Tel: +82-2-970-1289, Fax: +82-2-970-2410, hyejin@kcch.re.kr
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Hepatitis B virus (HBV) reactivation has previously occurred in hepatitis B surface antigen-negative patients with malignant lymphoma who received rituximab-based combination chemotherapy. However, few reports have described cases of HBV reactivation in patients with multiple myeloma thus far. We report a case of HBV reactivation in a patient with multiple myeloma treated with chemotherapy, autologous hematopoietic stem cell transplantation, and maintenance steroid therapy. For the HBV reactivation, the patient was treated with the antiviral agent entecavir. The clinical symptoms and laboratory findings improved after 3 months. Further studies should target the identification of patients at high risk of HBV reactivation in multiple myeloma treated with autologous hematopoietic stem cell transplantation and steroid therapy for maintenance and establish viral prophylaxis strategies, especially in Korea, in which HBV infection is endemic.
Keywords HBV reactivation, Multiple myeloma, Transplantation, Prednisolone, Chemotherapy
Blood Res 2015; 50(1): 51-53
Published online March 31, 2015 https://doi.org/10.5045/br.2015.50.1.51
Copyright © The Korean Society of Hematology.
Ha Ra Gu, Dong-Yeop Shin, Hong Seok Choi, Chae Ho Moon, Su Cheol Park, and Hye Jin Kang*
Department of Internal Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, Korea.
Correspondence to: Correspondence to Hye Jin Kang, M.D. Division of Hematology/Oncology, Department of Internal Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, 75 Nowon-gil, Nowon-gu, Seoul 139-706, Korea. Tel: +82-2-970-1289, Fax: +82-2-970-2410, hyejin@kcch.re.kr
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Hepatitis B virus (HBV) reactivation has previously occurred in hepatitis B surface antigen-negative patients with malignant lymphoma who received rituximab-based combination chemotherapy. However, few reports have described cases of HBV reactivation in patients with multiple myeloma thus far. We report a case of HBV reactivation in a patient with multiple myeloma treated with chemotherapy, autologous hematopoietic stem cell transplantation, and maintenance steroid therapy. For the HBV reactivation, the patient was treated with the antiviral agent entecavir. The clinical symptoms and laboratory findings improved after 3 months. Further studies should target the identification of patients at high risk of HBV reactivation in multiple myeloma treated with autologous hematopoietic stem cell transplantation and steroid therapy for maintenance and establish viral prophylaxis strategies, especially in Korea, in which HBV infection is endemic.
Keywords: HBV reactivation, Multiple myeloma, Transplantation, Prednisolone, Chemotherapy
Changes in the liver function panel after entecavir treatment.
Kyoung Cheon Kim, Hong Seok Lee, Yong Seok Jang, Won Sik Lee, Hong Suk Song
Korean J Hematol 2002; 37(2): 158-160Haerim Chung, Hyunsoo Cho
Blood Res 2023; 58(4): 166-172Ja Min Byun, Sung-Soo Park, Sung-Soo Yoon, Ari Ahn, Myungshin Kim, Jung Yeon Lee, Young-Woo Jeon, Seung-Hwan Shin, Seung-Ah Yahng, Youngil Koh, Chang-Ki Min
Blood Res 2023; 58(2): 83-90
Changes in the liver function panel after entecavir treatment.